Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/61731
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance
Author: Gold, M.
Buttery, J.
McIntyre, P.
Citation: Sexual Health, 2010; 7(3):320-324
Publisher: Csiro Publishing
Issue Date: 2010
ISSN: 1448-5028
1449-8987
Statement of
Responsibility: 
Michael S. Gold, Jim Buttery and Peter McIntyre
Abstract: Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.
Keywords: adverse events following immunisations
HPV vaccine
vaccine safety
Rights: Copyright CSIRO 2010
DOI: 10.1071/SH09153
Published version: http://dx.doi.org/10.1071/sh09153
Appears in Collections:Aurora harvest 5
Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.